C - Chemistry – Metallurgy – 12 – P
Patent
C - Chemistry, Metallurgy
12
P
C12P 21/08 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/30 (2006.01) C12N 1/15 (2006.01) C12N 1/19 (2006.01) C12N 1/21 (2006.01) C12N 5/10 (2006.01) C12N 15/09 (2006.01)
Patent
CA 2700986
A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an effective component the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an effective component are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an effective component the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an effective component.
L'invention concerne un procédé de régulation de la demi-vie d'un anticorps anti-glypican-3 dans le plasma, une composition pharmaceutique comprenant, comme ingrédient actif, un anticorps anti-glypican-3 dont la demi-vie dans le plasma est régulée, un procédé de production de l'anticorps anti-glypican-3, et un procédé de production d'une composition pharmaceutique comprenant, comme ingrédient actif, l'anticorps anti-glypican-3. Elle concerne un procédé de régulation de la demi-vie d'un anticorps anti-glypican-3 dans le plasma par modification d'un résidu d'acide aminé exposé à la surface de l'anticorps anti-glypican-3, un anticorps anti-glypican-3 dont la demi-vie dans le plasma est régulée par modification d'un résidu d'acide aminé, une composition pharmaceutique comprenant l'anticorps comme ingrédient actif, et un procédé de production de la composition pharmaceutique.
Igawa Tomoyuki
Ishiguro Takahiro
Kuramochi Taichi
Shiraiwa Hirotake
Tachibana Tatsuhiko
Chugai Seiyaku Kabushiki Kaisha
Smart & Biggar
LandOfFree
Anti-glypican-3 antibody having improved kinetics in plasma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-glypican-3 antibody having improved kinetics in plasma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-glypican-3 antibody having improved kinetics in plasma will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1974222